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Abstract
Background: The aim of this global collaboration was to develop a consensual set of items for the analysis of
synovial biopsies in clinical practice and translational research through the EULAR Synovitis Study Group (ESSG) and
OMERACT Synovial Tissue Biopsy Group.
Methods: Participants were consulted through a modified Delphi method. Three sequential rounds occurred over
12months. Members were sent a written questionnaire containing items divided into two parts. Items were identified
and formulated based on a scoping review. The first part of the questionnaire referred to synovial biopsies in clinical
practice including five subsections, and the second part to translational research with six subsections. Every participant
was asked to score each item on a 5-point Likert scale. Items with a median score above 3.5 and a≥ 70% agreement
were selected for the next round. The last round was conducted orally at EULAR in June 2017.
Results: Twenty-seven participants from 19 centers were contacted by email. Twenty participants from 17 centers
answered. Response rates for next rounds were 100%. For the first part relating to clinical practice, 20/44 items (45.5%)
were selected. For the second part relating to translational research, 18/43 items (41.9%) were selected for the final set.
Conclusions: We herein propose a consensual set of analysis items to be used for synovial biopsies conducted in
clinical practice and translational research.
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Introduction
The synovial tissue is the target organ of many rheum-
atic diseases such as rheumatoid arthritis (RA). The role
of synovial tissue biopsy is to provide a better under-
standing of disease pathophysiology, facilitate discovery
of new biomarkers for diagnosis and/or prognosis and
identification of new therapeutic targets [1].
Synovial biopsies (SB) have been increasingly performed
over the past few years; performed for both clinical and re-
search purposes. It is well-established that SB procedures
are acceptable and well tolerated by patients, independ-
ently from the biopsy method [2, 3]. We have reported
previously that SB may be useful in clinical practice [4]. In
translational research, SB may be characterised and classi-
fied according to their cellular signature, the pathotype [5,
6]. Pathotypes are correlated with molecular signatures
and synovial pathobiology is a promising biomarker for
disease stratification and predicting the course of disease in
RA [1]. Moreover, analyses of SB at both cellular and mo-
lecular levels offer a promising approach for personalised
therapy in RA [1, 7]. It is highly probable that synovial
biopsies will be performed more frequently in the future,
and strategies including synovial tissue analysis as a central
element for therapeutic decision making in RA are
currently under development.
Considering this, and even though SB are performed by
an increasing number of colleagues at rheumatology cen-
tres, a certain degree of heterogeneity remains in handling
and analytical procedures. Harmonisation of SB handling
and analytical procedures is crucial, to ensure reliability
and reproducibility of the findings across different centres.
Previous consensus efforts arose from EULAR Synovitis
Study Group (ESSG) and Outcomes Measures for
RheumAtology Clinical Trials (OMERACT) on synovial
biopsy for evaluation of treatment in clinical trials [8].
These recommendations provide detailed standardised
operating procedures for sample handling, however, they
do not address either scoring of samples for cellular/im-
munological infiltrates or reporting of data concerning
synovial tissue basic/translational research.
The aim of this study was to develop a process of
standardisation of SB procedures. Using a modified Del-
phi process [9], we aimed to achieve a consensual set of
items related to SB handling and analysis in both clinical
practice and translational research settings. This work
focused therefore on biopsy analysis and will not address
biopsy retrieval methods.
Methods
Background work
The items were identified and formulated based on a
comprehensive literature review. Item formulation was
based on published articles or a centre’s experience and
existing standardised operated procedures.
A task force (TF) of ESSG and OMERACT synovial
tissue special interest group (SIG) members was consti-
tuted and TF members were consulted through a
two-stage eDelphi process.
Questionnaire
TF members were sent a written questionnaire contain-
ing items divided into two parts.
The first part of the questionnaire referred to clinical
practice containing five subsections: biopsy sampling, bi-
opsy handling, histological analysis, staining and immu-
nohistochemistry (IHC), biopsy analysis and evaluation
by the pathologist (Additional file 1: Table S1).
The second part referred to translational research and
contained six subsections: biopsy sampling, biopsy hand-
ling, histological analysis, staining and IHC, biopsy analysis
and evaluation by the pathologist, ribonucleic acid (RNA)
analysis (Additional file 2: Table S2).
In the first and second rounds, every participant was
asked to score each item on a 5-point Likert scale (1:
strongly disagree, 2: disagree, 3: neither/neutral, 4: agree,
5: strongly agree), and comments were allowed for each
item. Following each round, anonymised detailed results
were communicated to participants by email.
Items with a median score above 3.5 out of 5 and a
percentage of agreement above 70% were selected for the
next round. Items with lower score were either suppressed
of modified according to participants’ comments. Items
could be added only in first round.
First round
The first questionnaire was administered by email to the
participants in June 2016.
Two email reminders were sent between June and
October.
Participants were invited to comment on the items
they disagreed with. Results of the first-round questionnaire
were presented at the ESSG meeting in November 2016 at
the American College of Rheumatology meeting in San
Francisco, CA, USA.
Second round
The second questionnaire was administered by email to
participants in December 2016 (Additional file 3).
Results of the second-round questionnaire were
presented at the ESSG meeting in June 2017 at the
EULAR annual conference in Madrid.
Face-to-face meeting
The face-to-face meeting occurred at the ESSG meeting in
June 2017 at the EULAR annual conference in Madrid.
Anonymised detailed results were sent to participants by
email. This face-to-face meeting constituted a third oral
round organised as follows: results were first presented
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and then discussed, seeking for a general agreement on
the final set of items.
Analysis
Items with a median score above 3.5 and percentage of
agreement above 70% were selected for further rounds.
Statistics were performed through GraphPad Prism 6.0
(GraphPad Software, San Diego, CA, USA).
Results
First round
Twenty-seven ESSG members from 19 centres were
contacted by email. Twenty participants from 17 centres
responded (response rate of 74%). Nineteen participants
(95%) were rheumatologists, one participant was a
pathologist (5%). Some centres (3/17) provided answers
based on a consensus of the entire research team (clinician
and translational scientists).
The first questionnaire contained 44 items for “Part 1
- Clinical practice”. Twenty-three items (52.3%) were
selected for the second round based on their score and
agreement percentage. Five items remained unchanged,
16 were modified according to participants’ comments
and two were added based on participants’ suggestion.
The first questionnaire contained 43 items for the
“Part 2 - Translational research”. Nineteen items (44%)
were selected for second round based on their score and
agreement percentage. Ten remained unchanged, nine
were modified according to participants’ comments,
none was added (Fig. 1).
Second round
For “Part 1 - Clinical practice”, 20/24 items (83.3%) were
selected for the third round.
For “Part 2 - Translational research”, 18/19 items
(95%) were selected for third round (Table 1).
Face-to-face meeting
Results of the second round were disseminated through
participating members and orally presented to the task
force at the ESSG meeting in June 2017. All task force
members agreed on the final set of items, as shown in
Table 1.
Items for clinical practice and translational research
Biopsy sampling
For the number of biopsies to be retrieved in joints, a mini-
mum of three biopsies in large joints and of two biopsies
in small joints was suggested. Nine respondents suggested
to retrieve two to six biopsies, four respondents suggested
to retrieve eight to 20 biopsies depending on size on the
joints. For second round, to facilitate agreement, we used
data previously published for translational research and
suggested six biopsies to be retrieved for large joints and
four biopsies for small joints.
There was some divergence in expert opinions on the
need to retrieve biopsy in different areas of the joints.
Some previous work suggested good correlations be-
tween the joint compartments in terms of histological
analysis for cluster of differentiation (CD)68 and factor
VIII (FVIII) staining [10]. Another recent work showed
that a similar T cell clone exists at different regions
Fig. 1 Flow chart. IHC immunohistochemistry, RNA ribonucleic acid
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within one joint [11]. On the other hand, it has been
shown that expression of pro-inflammatory cytokines
expression can vary within the same joint [12]. To facili-
tate agreement, we suggested to retrieve biopsies from
different areas of the joint, when possible.
Many agreed that bacteriological, fungal, mycobacter-
iology analyses and polymerase chain reaction (PCR) for
RNA 16S detection, Lyme and Whipple disease detec-
tion to be performed only when clinically relevant and
not for every patient.
Biopsy processing
There was a strong agreement that biopsies should
spend at least 24 h in formalin 4%. It was agreed that at
least two biopsies should be formalin-embedded, but
there was divergence in experts’ opinion regarding the
necessity of snap-freezing biopsies in clinical practice.
Regarding translational research, the number of biopsies
to be formalin-embedded or snap-frozen was controversial
and did not reach consensus. Minimal required thickness
of sections was also variating from 3 and 7 μm depending
on centres and this item did not reach consensus.
Histological criteria
There was support for requirements regarding histological
quality criteria. We suggest a biopsy size above 2.5mm2, a
preserved lining layer as quality criteria and the overall
morphology of the tissue to be preserved. Items regarding
minimal requirements in the number of vessels, or
percentage of stroma within the tissue required for quality
check did not reach consensus.
Staining and immunohistochemistry
In the context of clinical practice, haematoxylin and eosin
(H&E) and CD68 staining were considered to be sufficient
for histopathologic analysis although some additional stain-
ing such as CD20, CD3, CD138, FVIII or CD31 could be
used when clinically relevant. A semi-quantitative analysis
Table 1 Final set of items for both clinical practice and translational research
Clinical practice Translational research
1. Biopsy sampling
- A minimum of four synovial biopsies needs to be retrieved in small
joints.
- Biopsies shall be retrieved in different areas of the joint, if possible.
- If it is clinically relevant, bacteriological, fungal and mycobacteriological
assessment should be performed.
- Polymerase chain reaction analysis for RNA 16S should be performed
if clinically relevant, especially if empiric antibiotic course has been
started.
- If it is clinically relevant, polymerase chain reaction analysis for Lyme
and Whipple diseases should be performed.
2. Biopsy processing
- The biopsies should spend 24 h in formalin 4%.
- At least two biopsies should be formalin-fixed and paraffin-embedded.
3. Histological criteria
- Synovial biopsy surface should be more than 2.5 mm2.
- A lining layer should be seen.
- Morphology of the synovial tissue should be preserved.
4. Staining and immunohistochemistry (IHC)
- H&E staining should always be performed.
- CD68 staining should be performed.
- In particular clinically relevant cases, additional staining should be
performed (CD3, CD20, CD138, CD31 or FVIII).
- If performed, IHC results can be given using a semi-quantitative score.
5. Biopsies interpretation and pathologist’s report
- A synovitis score should be performed, analysing: lining layer
hyperplasia, inflammatory infiltrate and resident cell activation
(Krenn, other).
- Synovial pathotype should be described.
- Presence or absence of lymphoid follicles within the membrane
should be described.
- Analysis can be semi-quantitative or quantitative depending on the
question.
- If a semi-quantitative or quantitative analysis is performed for multiple
biopsies, an average score should be calculated and given for the
analysis of inflammation and vascularisation.
- The pathologist should mention the presence of granulomas
1. Biopsy sampling
- A minimum of six synovial biopsies needs to be retrieved in large
joints.
- A minimum of four synovial biopsies needs to be retrieved in small
joints
- Biopsies shall be retrieved in different areas of the joint, if possible.
2. Biopsy processing
- The biopsies should spend 24 h in formalin 4%*.
3. Histological criteria
- Synovial biopsy surface should be more than 2.5 mm2.
- A lining layer should be seen.
- Morphology of the synovial tissue should be preserved.
4. Staining and IHC
- H&E staining should always be performed.
- CD68 staining should be performed.
- CD3, CD19 or CD20 staining should be performed.
- Additional CD 31 or FVIII, CD4, CD8, CD138 staining might be
performed depending on the question.
5. Biopsies interpretation and Pathologist’s report
- A synovitis score should be performed, analysing: lining layer
hyperplasia, inflammatory infiltrate and resident cell activation
(Krenn, other).
- Lining layer hyperplasia should be scored.
- Synovial pathotype should be described.
- Presence or absence of lymphoid follicles within the membrane
should be described.
- Analysis can be semi-quantitative or quantitative depending on
the question.
- If a semi-quantitative or quantitative analysis is performed for a
single biopsy: at least three areas of the biopsy should be assessed.
6. RNA analysis
- Biopsies of one patient can be pooled for RNA extraction if needed.
*This item refers to those biopsies where a decision has been made to process in formalin
CD cluster of differentiation, FVIII factor VIII, H&E haematoxylin and eosin, IHC immunohistochemistry, RNA ribonucleic acid
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method was felt as sufficiently accurate and less time-con-
suming in clinical practice, although a quantitative analysis
can be performed when required by the clinical context.
Some previous work suggested that CD15 infiltrate could
be strongly associated with infectious arthritis diagnosis
[13]. Although some participants were strongly supportive
of the use of CD15 staining when infectious arthritis was
suspected, this item did not reach consensus (39.2%).
In the context of translational research, H&E, CD68,
CD19 or CD20, CD3 were considered as highly relevant
and required, although CD138, FVIII or CD31, CD4, or
CD8 could be used depending on the scientific question.
Regarding the analysis, it was argued during the meeting
that previous work showed satisfactory correlation coeffi-
cients between different scoring methods, semi-quantitative
or quantitative [14], and so the choice of the scoring
method should depend on the question.
Biopsy interpretation and pathologist report
It was agreed that a synovitis score should be performed
but no preference was expressed regarding the score to be
used (Krenn synovitis score [15], other score). Lining layer
hyperplasia scoring was recommended only for transla-
tional research purposes. Respondents overall agreed that
synovial pathotype should be described although some of
them emphasised that it was still not clear which features
made the synovial pathotype. It was strongly felt that the
presence or absence of ectopic lymphoid follicles within the
membrane should be described. For clinical practice, diver-
gent opinions were expressed regarding the need for the
pathologist to suggest the likeliest diagnosis and this item
finally did not reach consensus (66.7%). Some respondents
argued that this should occur only when the diagnosis
depended solely on the histological analysis. Conversely,
mentioning the presence of granulomas was considered of
importance by the panel. When multiple biopsies were ana-
lysed, a majority of respondent felt that results should be
expressed as average score of the total number of biopsies
analysed. For translational research, variability within the
same biopsy of cell infiltrate was a matter of debate. We
recommend that if a single biopsy is to be analysed, at least
three different areas need to be assessed to ensure more
reliability.
Although some participants were strongly supportive of
assessing vascularity in clinical practice through semi-
quantitative score, or translational research through the
number of vessels per square millimetre or per high-power
field, these items did not reach consensus (66.6% and
61.1%) (Additional file 4: Table S3).
Items for translational research
RNA analysis
It was agreed by the panel that biopsies of one patient
can be pooled for RNA extraction if needed.
Discussion
Standardisation of SB analysis procedures is an important
objective in the synovial tissue field and we felt it was
important to combine expertise of the existing working
groups: ESSG and OMERACT Synovial Tissue Biopsy
Group.
In this work, we used a validated consensus method
through subsequent rounds in order to achieve a consen-
sus. The Delphi method is widely used in order to create
recommendations not only in the field of rheumatology
but also in other specialties [16–19].
This approach, by preserving experts’ answers anonym-
ity, has the advantage to be less subject to peer-pressure
and reduces bias.
In the current work, although there were disparities in
protocols and in the number of participating experts from
numerous centres, most of the items achieved consensus.
This being said, the Delphi outcome can somehow
vary depending on the number of rounds [20]. We tried
to address these biases by finalising the Delphi process
with a face-to-face meeting to discuss and endorse the
final set of recommendations.
The standardisation of SB procedures is an important
objective for both clinical practice and translational re-
search, to ensure comparability of the assessment and the
reported results in multicentric studies. Extensive work
has been done by the ESSG and OMERACT Synovial
Tissue Biopsy Group in the past years regarding biopsy
analysis and minimal requirements for clinical trials [21,
22]. Unanswered questions, however still remain. To date,
despite the existence of data to support the number of bi-
opsies to be performed in a joint or consensus on tech-
nical modalities in tissue handling [23–25], consensus is
still lacking in other areas, such as minimal reporting in
tissue analysis or quality requirements. Moreover, recom-
mendations are lacking in the use of biopsies in clinical
practice.
The number of centres performing synovial biopsy for
clinical purposes is lower as the mini-arthroscopy tech-
nique is mostly used in the research setting in rheuma-
tology. This implies that items related to clinical practice
were formulated mostly based on expert opinion and
this might represent a limitation of this work.
Providing such standardisation might, on the other
hand, encourage further spreading of the biopsy proce-
dures and generate new scientific data.
Some points that did not reach consensus in this work
should be considered as specific areas for further re-
search, for example to generate data to support decisions
regarding ideal section thickness or the minimum num-
ber of area to be biopsied within the joint.
Many of the items presented in the final core set are
consistent with the scientific work previously published, in
terms of number of biopsies to be retrieved in large and
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small joints and the need for retrieval in different areas of
the joint [8, 22]. Items relative to biopsy processing and
histological quality requirement also displayed a high level
of agreement. We observed that agreement was less fre-
quently reached for items relating to histological analysis
and immunohistochemistry. This might be explained by
the fact that the immunohistochemistry performed and
the scoring method used relied on the purpose of the
scientific work. Indeed, two items related to vascularity
scoring did not reach 70% of agreement after two rounds
(agreement of 67 and 61% with median score of 3.5). This
was discussed during the face-to-face meeting and it was
decided that this should not prevent further use of
vascularity analysis and scoring when relevant.
It is worth noting that most of the task force partici-
pants derived from the rheumatology field, as the vast
majority of the centres with interest in synovial biopsies
are rheumatology centres. We also invited a pathologist
and a scientist with interest in synovial tissue analysis
into the Task Force. The opinions did not diverge
between participants regardless their background.
Despite some limitations, this consensus study provides
further guidance towards standardisation of handling and
analysis procedures. In future studies, different approaches
could be used, in order to reduce the limitations of the
Delphi approach. One approach might be to propose an
approach involving two task force meetings, the first one
to formulate the Delphi items and then a voting phase,
finalised by a second Task Force meeting as we did.
Further step for the OMERACT Synovial Tissue
Biopsy and ESSG groups will involve assessment and
harmonisation of synovial tissue histological markers
analysis to assess whether these can guide choices
appropriate therapeutic agents, predict responses to treat-
ment, and define a consensual set of histological items to
be used for prediction of treatment responses in RA.
This work also lays the ground for further standardisation
efforts in the field. The research agenda of the working
groups includes a formal proposal for points to consider for
minimal quality and analysis reports on synovial biopsy.
Conclusions
In summary, we herein provide a set of consensual items
on methods for synovial tissue biopsy analysis in both
clinical practice and translational research, as a step to-
wards standardisation of biopsy handling and analysis
procedures across centres.
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